Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Jackson

Showing results (171-180 of 182) with videos related to

Pageof 19
Sort By:
Journal of Asthma and Allergy|October 28, 2022
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic TherapyWenjia Chen, Mohsen Sadatsafavi, Trung N Tran, et al.
Allergy|June 26, 2024
Real-world biologics response and super-response in the International Severe Asthma Registry cohortEve Denton, Mark Hew, Matthew J Peters, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2023
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma RegistryWenjia Chen, Trung N Tran, Mohsen Sadatsafavi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 9, 2024
Reply to "Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry"Wenjia Chen, Trung N Tran, Mohsen Sadatsafavi, et al.
Allergy|March 17, 2023
Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for bothPaul E Pfeffer, Nasloon Ali, Ruth Murray, et al.
The European Respiratory Journal|November 7, 2024
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthmaEkaterina Khaleva, Chris Brightling, Thomas Eiwegger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 3, 2025
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approachEileen Wang, William Henley, Désirée Larenas-Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine|November 28, 2023
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe AsthmaMichael E Wechsler, Ghislaine Scelo, Désirée E S Larenas-Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine|May 18, 2025
Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with BiologicsMohsen Sadatsafavi, Trung N Tran, Ghislaine Scelo, et al.
Frontiers in Immunology|May 7, 2024
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthmaCeleste M Porsbjerg, John Townend, Celine Bergeron, et al.
Pageof 19

Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Journal of Asthma and Allergy|October 28, 2022
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic TherapyWenjia Chen, Mohsen Sadatsafavi, Trung N Tran, et al.
Allergy|June 26, 2024
Real-world biologics response and super-response in the International Severe Asthma Registry cohortEve Denton, Mark Hew, Matthew J Peters, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 10, 2023
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma RegistryWenjia Chen, Trung N Tran, Mohsen Sadatsafavi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 9, 2024
Reply to "Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry"Wenjia Chen, Trung N Tran, Mohsen Sadatsafavi, et al.
Allergy|March 17, 2023
Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for bothPaul E Pfeffer, Nasloon Ali, Ruth Murray, et al.
The European Respiratory Journal|November 7, 2024
Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthmaEkaterina Khaleva, Chris Brightling, Thomas Eiwegger, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 3, 2025
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approachEileen Wang, William Henley, Désirée Larenas-Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine|November 28, 2023
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe AsthmaMichael E Wechsler, Ghislaine Scelo, Désirée E S Larenas-Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine|May 18, 2025
Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with BiologicsMohsen Sadatsafavi, Trung N Tran, Ghislaine Scelo, et al.
Frontiers in Immunology|May 7, 2024
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthmaCeleste M Porsbjerg, John Townend, Celine Bergeron, et al.
Pageof 19